- Home
- EDUC vs AKTX Comparison
EDUC vs AKTX Comparison
Compare EDUC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDUC | AKTX |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 14.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EDUC | AKTX |
|---|---|---|
| Price | $1.39 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 24.8K | ★ 1.3M |
| Earning Date | 01-08-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $25,371,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.22 |
| 52 Week High | $1.91 | $1.73 |
Technical Indicators
Market Signals| Indicator | EDUC | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 39.19 |
| Support Level | $1.35 | $0.26 |
| Resistance Level | $1.58 | $0.31 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 57.14 | 43.08 |
Price Performance
Historical ComparisonAbout EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.